Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Non-Current Assets (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Non-Current Assets data on record, last reported at $17.4 million in Q1 2026.

  • On a quarterly basis, Non-Current Assets rose 34.22% to $17.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $67.8 million, a 35.51% increase, with the full-year FY2025 number at $18.0 million, up 43.75% from a year prior.
  • Non-Current Assets reached $17.4 million in Q1 2026 per OLMA's latest filing, down from $18.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for OLMA hit a ceiling of $18.1 million in Q3 2025 and a floor of $6.1 million in Q2 2023.
  • A 5-year average of $11.3 million and a median of $11.6 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 595.37% in 2022, then fell 19.26% in 2023.
  • Tracing OLMA's Non-Current Assets over 5 years: stood at $6.7 million in 2022, then soared by 54.64% to $10.4 million in 2023, then rose by 19.88% to $12.5 million in 2024, then surged by 43.75% to $18.0 million in 2025, then dropped by 3.13% to $17.4 million in 2026.
  • Business Quant data shows Non-Current Assets for OLMA at $17.4 million in Q1 2026, $18.0 million in Q4 2025, and $18.1 million in Q3 2025.